Loading...

5-year outcomes from PlanB: Phase 3 trial of 21-gene Recurrence Score® result in breast cancer

82 views

Loading...

Loading...

Transcript

The interactive transcript could not be loaded.

Loading...

Rating is available when the video has been rented.
This feature is not available right now. Please try again later.
Published on Jun 3, 2016

At the 10th European Breast Cancer Conference (EBCC), held in Amsterdam, the Netherlands, from 9 to 11 March 2016, Oleg Gluz, MD, from the West German Study Group, Mönchengladbach, Germany, discusses the 5-year disease-free survival, defined as relapse, secondary malignancy or death, of patients with node-positive and high-risk node-negative early breast cancer who omitted adjuvant chemotherapy based on an Oncotype DX® 21-gene Recurrence Score® result of 11 or less in PlanB, a prospective phase 3 trial evaluating the Recurrence Score® result.

This content is supported by Genomic Health, Inc.

Loading...

When autoplay is enabled, a suggested video will automatically play next.

Up next


to add this to Watch Later

Add to

Loading playlists...